Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.38% | 5.34% | 9.44% | 27.86% | -9.39% |
| Total Depreciation and Amortization | -5.08% | -1.56% | -1.65% | -30.75% | 4.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.23% | -32.40% | 4.78% | -72.72% | 103.82% |
| Change in Net Operating Assets | 109.33% | 590.41% | 101.36% | -181.46% | -161.03% |
| Cash from Operations | 4.35% | 0.87% | 27.28% | -21.62% | 5.51% |
| Capital Expenditure | 45.89% | -61.75% | -13.88% | -1,120.41% | 80.20% |
| Sale of Property, Plant, and Equipment | 7,800.00% | -97.54% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.78% | 12.68% | -52.52% | 91.45% | -11.72% |
| Cash from Investing | 29.89% | 8.58% | -54.09% | 87.03% | -10.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.72% | 86.79% | -- | -- | -- |
| Cash from Financing | -31.72% | 86.79% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,057.89% | 82.92% | -141.41% | 578.36% | 53.18% |